<DOC>
	<DOC>NCT02184247</DOC>
	<brief_summary>Study to compare the bioavailability of 350 mg Bronchoretard® - a sustained-release theophylline (anhydrous) product with respect to the reference product, Theo Dur® 300 mg theophylline anhydrous (sustained-release product) by comparing the rate and extent of absorption of theophylline based on both single and multiple-dose profiles.</brief_summary>
	<brief_title>Bioavailability of Two Sustained-release Theophylline Products in Healthy Males</brief_title>
	<detailed_description />
	<mesh_term>Theophylline</mesh_term>
	<criteria>Healthy, nonsmoking male subjects between 18 and 45 years of age Body weight within 10% of the ideal weight according to the Body Mass Index (BMI) Normal health based on medical history and findings within the range of clinical acceptability, in respect of the physical examination (including electrocardiogram and vital signs) and special investigations Ability to comprehend and willingness to sign both statements of informed consent (for screening and studyspecific procedures) History of serious systemic or organ disease A major illness during the 3 months before commencement of the studyrelated procedures Significant physical or organ abnormality History of hypersensitivity to theophylline or other xanthine derivatives Use of any medication within 2 weeks before the first administration of study medication Participation in another study with an experimental drug within 8 weeks before the first administration of study medication Treatment within the previous 3 months with any drug with a welldefined potential for adversely affecting a major organ or system (for example chloramphenicol, which may cause bone marrow suppression) Donation of blood during the 8 weeks before the first administration of study medication History of, or current compulsive alcohol abuse (&gt; 10 drinks per week), of regular exposure to other substance of abuse Positive testing for HIV and hepatitis B antigens within the previous 3 months</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>